New research is shedding light on why many patients with chronic spontaneous urticaria (CSU) remain hesitant to adopt advanced treatments, even as newer biologic and targeted therapies show promise in ...

Patients with moderate to severe CSU have greater rates of several immune-mediated comorbidities than patients with mild CSU.

Learn to recognise chronic hives (urticaria), its symptoms, and how it differs from allergies for timely diagnosis and ...

Dupilumab shows significant efficacy in reducing itch and hives in CSU patients unresponsive to antihistamines. The CUPID A and CUPID C trials reported a two-thirds reduction in itch and urticaria ...

NEW YORK — The responsibility for diagnosing and treating chronic spontaneous urticaria (CSU), for which there is a newly approved drug, should be in the hands of dermatologists who have the skills, ...

"By capturing key PROs, these tools underscore the importance of focusing on patient experiences to optimize management strategies for CSU, thereby enhancing patient care and outcomes… The traditional ...

Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in ...

"[Physicians] should advise patients that [CSU] is not a life-threatening disease, often occurs due to autoimmunity, and typically resolves within several years [and patients] should also be referred ...

During the Conversations in Dermatology 2025 conference, expert physicians who manage pruritic conditions will discuss challenging cases and the latest developments for the treatment of chronic ...